Helicases are essential enzymes that unwind DNA and RNA duplexes, playing critical roles in processes such as DNA replication, repair, recombination, and transcription. Given their pivotal role in maintaining genomic stability, helicases have emerged as promising therapeutic targets for a range of diseases, including cancer, viral infections, and genetic disorders. Targeting helicases can disrupt these vital processes in pathogens or cancer cells, offering a new approach to treatment.
Protein: High-quality production of helicases.
Biochemical: ADP-Glo and unwinding assays to assess helicase activity.
Biophysical: SPR and MST-TRIC assays for detailed kinetic studies of helicase interactions.
Protein Degradation: Specialized detection assays for analyzing helicase degradation.
Cell Based Assays: Robust cell-based assays to evaluate the cellular effects of helicase modulation.
CDX and Resistance Models: Development and use of CDX models and resistance models for in vivo studies on helicase-targeting compounds.
Here, we highlight WRN helicase as an example to showcase our capabilities and service offerings.
WRN helicase, a member of the RecQ family, is crucial for DNA replication, repair, recombination, and telomere maintenance. Mutations in WRN lead to Werner syndrome, associated with premature aging and cancer predisposition. Targeting WRN in cancer therapy, particularly in tumors with microsatellite instability (MSI), has shown promising therapeutic potential.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
